

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

OVERSEAS REGULATORY ANNOUNCEMENT

This overseas regulatory announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”) will published the “*Announcement on having obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information*” on CNINFO <http://www.cninfo.com.cn> (巨潮資訊網) on 10 May 2025. The English translation of the relevant document is hereby included for reference. If there is any inconsistency between the English version and the Chinese version, the Chinese version shall prevail.

By Order of the Board

Shandong Xinhua Pharmaceutical Company Limited

He Tongqing

Chairman

9 May 2025, Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. He Tongqing (*Chairman*)

Mr. Xu Wenhui

Mr. Hou Ning

Independent Non-executive Directors:

Mr. Pan Guangcheng

Mr. Zhu Jianwei

Mr. Ling Peixue

Ms. Cheung Ching Ching, Daisy

Non-executive Directors:

Mr. Xu Lie

Mr. Zhang Chengyong

Shandong Xinhua Pharmaceutical Company Limited**Announcement on having obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information**

The Company and its board of directors confirm that the contents of this announcement are true, accurate and complete without any false information, misleading statements or material omissions.

Shandong Xinhua Pharmaceutical Company Limited (hereinafter referred to as “**Xinhua Pharmaceutical**” or the “**Company**”) has recently received the *Notification of Approval of Supplementary Drug Application* (药品补充申请批准通知书) issued under the authority of the National Medical Products Administration (药品审评中心) in connection with the approval of change of marketing licence holder of its Epalrestat Tablets (hereinafter referred to as, the “**Product**”). Relevant information is now announced as follows:

I. Basic information

Drug name:	Epalrestat Tablets
Dosage form:	Tablet
Specification:	50mg
Drug classification:	Prescription drugs
Applicant:	Shandong Xinhua Pharmaceutical Company Limited
Application matter:	Application for change of marketing licence holder
Reception number:	CYHB2500728
Drug approval number:	National Medicine Zhunzi (国药准字) H20253176
Notification number:	2025B01957
Approval Conclusion:	According to the Drug Administration Law of the People’s Republic of China and applicable regulations, upon review, the application concerning the Product complies with applicable requirements for drug registration and it is agreed that the change of the marketing licence holder in connection therewith be approved in accordance with the relevant provisions of the <i>Measures for the Administration of Post-marketing Changes of Drugs (Trial)</i> .

II. Other relevant information

Xinhua Pharmaceutical and Jiangsu Dongke Kangde Pharmaceutical Company Limited (hereinafter referred to as “**Jiangsu Dongke Kangde**”) signed a production technology and MAH transfer contract in August 2023. According to the contract, Jiangsu Dongke Kangde shall make an one-off transfer of its license concerning the Marketing Authorization Holder (MAH) status of Epalrestat Tablets and all related technical ownership rights (including production approval documentation, intellectual property rights relating to production technology, commercialization rights and related rights and benefits etc., including but not limited to from the aspects of production technology, sales and marketing, etc.) to Xinhua Pharmaceutical. The total technology transfer fee shall be payable by Xinhua Pharmaceutical to Jiangsu Dongke Kangde in accordance with staged instalments

as stipulated under the contract.

Pursuant to the Rules Governing the Listing of Shares on Shenzhen Stock Exchange (深圳证券交易所股票上市规则) and the articles of association of the Company (公司章程), the present transaction is not required to be submitted for the review and approval of the board of directors or shareholders' meeting of the Company. The present transaction does not constitute a related party transaction, nor does it constitute a significant asset restructuring as stipulated in the *Measures for Administration of Material Assets Reorganization of Listed Companies* (上市公司重大资产重组管理办法).

In April 2025, Xinhua Pharmaceutical submitted application materials in connection with the change of marketing license holder of the Product to the National Medical Products Administration Drug Evaluation Center (CDE), and in May 2025, it received *Notification of Approval of Supplementary Drug Application* (药品补充申请批准通知书). The conclusion of the review evaluation is that the application for the transfer of holder of the Product complies with applicable requirements of post-listing administrative provisions, and the change of marketing licence holder of the Product was approved.

Epalrestat Tablets are indicated for use in connection with diabetic neuropathy. It belongs to the Class B variety of "National Basic Medical Insurance, Industrial Injury Insurance, and Maternity Insurance Drug List". According to relevant statistics, the sales of Epalrestat Tablets in China's public medical institutions amounted to approximately RMB1.803 billion in 2023.

III. Impact on the Company and risk warning

Xinhua Pharmaceutical obtained the Notification of Approval of Supplementary Drug Application in May 2025. Epalrestat Tablets received the approval of the National Medical Products Administration, and the Company became the marketing license holder of the Product. The launch of the Product will help enrich the Company's endocrine system drugs product line and enhance the Company's overall competitive advantage.

The pharmaceutical sales business is susceptible to changes in domestic pharmaceutical industry policies, bidding and procurement processes, changes in the market environment and other factors, and is subject to uncertainty. Investors are advised to invest sensibly and pay attention to investment risks.

By Order of the Board
**Shandong Xinhua Pharmaceutical
Company Limited**

9 May 2025